

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information only and is not intended to and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



INNOCARE

诺诚健华

InnoCare Pharma Limited

諾誠健華醫藥有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 9969)

**ANNOUNCEMENT ON
APPROVAL OF PROPOSED RMB SHARE ISSUE
BY THE LISTING COMMITTEE OF THE STAR MARKET**

This announcement is made by InnoCare Pharma Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the Company’s announcements dated 11 March 2021, 26 May 2021 and 13 September 2021, the Company’s overseas regulatory announcements dated 13 September 2021, 19 November 2021, 27 December 2021, 28 March 2022 and 4 April 2022, and the Company’s circular dated 3 June 2021 containing, among other things, related matters of the proposed initial public offering of the RMB Shares (the “**Proposed RMB Share Issue**”) and listing on the STAR Market of the Shanghai Stock Exchange (the “**SSE**”). Unless otherwise defined, capitalized terms used in this announcement shall have the meanings as defined in the above announcements and circular.

The Board hereby announces that the 27th review meeting of the listing committee for the STAR Market of the SSE in 2022 was held on 12 April 2022. In accordance with the review results of the meeting, the Proposed RMB Share Issue and listing on the STAR Market of the SSE by the Company has been approved by the listing committee of the STAR Market.

The RMB Share Issue is subject to, among other things, other necessary Regulatory Approvals and thus may or may not proceed. Shareholders and potential investors of the Company should be aware that there is no assurance that the RMB Share Issue will materialise or as to when it may materialise. Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company. Further announcement(s) will be made to disclose any material updates and developments in respect of the RMB Share Issue in accordance with the Listing Rules and other applicable laws and regulations as and when appropriate. This announcement is for information only and is not intended to and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for any securities of the Company.

By order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and executive Director

Hong Kong, 13 April 2022

As at the date of this announcement, the Board of Directors comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi, Mr. Ronggang Xie, Mr. Shan Fu and Mr. Ming Jin as non-executive Directors, and Dr. Zemin Zhang, Ms. Lan Hu and Dr. Kaixian Chen as independent non-executive Directors.